Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround

...

A 25-year-old biologist is launching a new company with $3.4 million in seed funding to develop a personalized cell therapy using the gene-editing tool CRISPR.

AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a China pharma that aims to treat lung disease.

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute, Eric Green, M.D., Ph.D., will now step into the commercial life sciences world as the new chief medical officer of Illumina.

Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year.

Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an ADC targeting the immune checkpoint protein.